Blood eosinophils and inhaled corticosteroid/longacting β-2 agonist efficacy in COPD

Thorax

Volumn 71, Issue 2, 2016, Pages 118-125

  Pavord, Ian D ^a   Lettis, Sally ^b   Locantore, Nicholas ^c   Pascoe, Steve ^c   Jones, Paul W ^d   Wedzicha, Jadwiga A ^e   Barnes, Neil C ^b,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING BETA 2 AGONIST; LONG ACTING DRUG; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; GLUCOCORTICOID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION; BLOOD; CYTOLOGY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; EOSINOPHIL; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84958985825     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207021     Document Type: Article

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2014. http://www.goldcopd. org/guidelines-global-strategy-for-diagnosis-management.html (accessed 2 Sep 2014).
2. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19:113-18.
3. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
4. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
5. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108.
6. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care ( partial update), 2010. http://www.nice.org.uk/ guidance/CG101/chapter/1-Guidance (accessed 2 Sep 2014).
7. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.
8. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:189-95.
9. Kostikas K, Bakakos P, Papiris S, et al. Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application? Curr Drug Targets 2013;14:177-91.
10. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646-52.
11. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13.
12. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
13. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-17.
14. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
15. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
16. Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44:789-91.
17. Chanez P, Vignola AM, O'Shaughnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34.
18. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23.
19. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42.
20. Wedzicha JA, Calverley PM, Seemungal TA, et al, the INSPIRE investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
21. GlaxoSmithKline. Clinical study register. SFCT 01/SCO30002. http://www. gsk-clinicalstudyregister.com/files/pdf/23674.pdf (accessed 19 Jan 2015).
22. GlaxoSmithKline. Clinical study register. SCO100540. http://www. gsk-clinicalstudyregister.com/study/100540#rs (accessed 2 Mar 2015).
23. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
24. GlaxoSmithKline. Clinical study register. SFCA3007. http://www. gsk-clinicalstudyregister.com/study/SFCA3007#csr (accessed 2 Mar 2015).
25. GlaxoSmithKline. Clinical study register. SCO100470. http://www. gsk-clinicalstudyregister.com/study/100470#csr (accessed 2 Mar 2015).
26. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s.